Skip to main content

Table 1 OS and PFS of patients with DLBCL in different primary sites

From: 5-Hydroxymethylation alterations in cell-free DNA reflect molecular distinctions of diffuse large B cell lymphoma at different primary sites

Primary site

n

3-year

5-year

PFS (%)

OS (%)

PFS (%)

OS (%)

LN-DLBCL

47

72.7

76.5

69.1

73.0

PG-DLBCL

56

73.5

83.7

70.4

72.9

PI-DLBCL

57

59.8

71.6

39.1

60.3

PT-DLBCL

28

64.4

72.1

46.0

63.1

PCNS-DLBCL

28

44.5

66.1

19.1

27.5

IP-DLBCL

56

54.1

68.3

30.7

44.8

Non-IP-DLBCL

160

68.6

77.8

59.6

69.3

  1. OS: Overall survival; PFS: progression-free survival; DLBCL: diffuse large B cell lymphoma; LN-DLBCL: lymph node-involved DLBCL; PG-DLBCL: primary gastric DLBCL; PI-DLBCL: primary intestinal DLBCL; PT-DLBCL: primary testicular DLBCL; PCNS-DLBCL: primary central nervous system DLBCL; and IP-DLBCL: primary immune-privileged site-associated DLBCL